Adaptive Biotechnologies Corporation (ADPT) stock analysis
In our weekly check, Adaptive Biotechnologies Corporation is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 10 pass, warnings: 2, red flags: 10.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ADPT.
What our checks show for ADPT
Red flags
- Debt is high against equity (2.32x). That limits room in a downturn.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- Earnings per share fell 31.4% a year over the last 3 years.
- The company is losing money: the net margin is -23.7%.
- Free cash flow is negative (-3% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 66.2% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 97% from a peak. Would you have held through that?
- Beta 2.15: the stock usually moves more than the market, both up and down.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Analysts expect earnings per share to shrink about 48.1% a year.
- The stock is still below its previous peak.
Strengths
- The net margin rose by 111 points over 5 years, to -23.7%.
- The gross margin is 74% and has risen by 6 points: pricing power is holding.
- Analysts expect revenue to grow about 21.5% a year over the next years.
- Analysts expect the net margin to improve by 28.4 points from today's -23.7%.
- Revenue grew 17.2% a year over the last 3 years.
- Actively traded: about 2.2 million shares a day.
Next earnings report: 2027-02-04
Similar companies
IONS · TVTX · EWTX · COGT · DFTX · TNGX
Questions
What grade does Adaptive Biotechnologies Corporation (ADPT) have?
In our weekly check, Adaptive Biotechnologies Corporation is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 10 pass, warnings: 2, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of ADPT stock?
This week's biggest flags for Adaptive Biotechnologies Corporation: High debt, Weak interest cover, Weak EPS growth. In total 12 of 22 checks show a warning or a red flag.
What does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies Corporation is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ADPT.
When does Adaptive Biotechnologies Corporation report earnings next?
The next earnings report is expected on 2027-02-04. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis